GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
- Conditions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1415
- Registration Number
- NCT00089986
- Locations
- π¬π§
GSK Investigational Site, Sheffield, United Kingdom
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 138
- Registration Number
- NCT00089999
- Locations
- π¨π³
GSK Investigational Site, Taipei, Taiwan
Study Of Ispinesib In Subjects With Breast Cancer
- First Posted Date
- 2004-08-20
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00089973
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
- Conditions
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT00086658
- Locations
- π¨π
GSK Investigational Site, Bern, Switzerland
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
- Conditions
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT00086593
- Locations
- π¬π§
GSK Investigational Site, Hull, United Kingdom
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
- Conditions
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 866
- Registration Number
- NCT00085943
- Locations
- π¨π
GSK Investigational Site, St Gallen, Switzerland
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00085904
- Locations
- πΊπΈ
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00085878
- Locations
- πΊπΈ
GSK Investigational Site, Philadelphia, Pennsylvania, United States
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00085813
- Locations
- π¬π§
GSK Investigational Site, Sutton, Surrey, United Kingdom
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
- Conditions
- First Posted Date
- 2004-05-10
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00082394
- Locations
- π²π½
GSK Investigational Site, Monterrey, Nuevo LeΓ³n, Mexico